These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 33232489)

  • 1. An unfavourable outcome following switching intravenous abatacept and tocilizumab to subcutaneous forms during the COVID-19 pandemic.
    Gupta R; Shipa M; Yeoh SA; Buck P; Ehrenstein MR
    Rheumatology (Oxford); 2021 Feb; 60(2):977-979. PubMed ID: 33232489
    [No Abstract]   [Full Text] [Related]  

  • 2. Are abatacept and tocilizumab intravenous users willing to switch for the subcutaneous route of administration? A questionnaire-based study.
    Desplats M; Pascart T; Jelin G; Norberciak L; Philippe P; Houvenagel E; Goeb V; Flipo RM
    Clin Rheumatol; 2017 Jun; 36(6):1395-1400. PubMed ID: 28255739
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Switch from intravenous to subcutaneous abatacept: Our experience.
    Nieto-González JC; Ovalles-Bonilla JG; Estrada E; Monteagudo I
    Reumatol Clin (Engl Ed); 2020; 16(2 Pt 2):187-188. PubMed ID: 29530763
    [No Abstract]   [Full Text] [Related]  

  • 4. [Cost-minimization analysis of subcutaneous abatacept in the treatment of rheumatoid arthritis in Spain].
    Ariza R; Van Walsem A; Canal C; Roldán C; Betegón L; Oyagüez I; Janssen K
    Farm Hosp; 2014 Jul; 38(4):257-65. PubMed ID: 25137158
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Switching from intravenous to subcutaneous formulation of abatacept: a single-center Italian experience on efficacy and safety.
    Reggia R; Franceschini F; Tincani A; Cavazzana I
    J Rheumatol; 2015 Feb; 42(2):193-5. PubMed ID: 25512476
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Experience of monitoring subcutaneous biological treatment (adalimumab) by nurses in chronic inflammatory diseases].
    Sánchez-Eslava L; Corominas H; Riera M; Fíguls R
    Reumatol Clin; 2011; 7(5):349-50. PubMed ID: 21925455
    [No Abstract]   [Full Text] [Related]  

  • 7. Comparative effectiveness of rituximab, abatacept, and tocilizumab in adults with rheumatoid arthritis and inadequate response to TNF inhibitors: prospective cohort study.
    Gottenberg JE; Morel J; Perrodeau E; Bardin T; Combe B; Dougados M; Flipo RM; Saraux A; Schaeverbeke T; Sibilia J; Soubrier M; Vittecoq O; Baron G; Constantin A; Ravaud P; Mariette X;
    BMJ; 2019 Jan; 364():l67. PubMed ID: 30679233
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety profile of intravenous tocilizumab versus intravenous abatacept in treating female Saudi Arabian patients with active moderate-to-severe rheumatoid arthritis.
    Elmedany SH; Mohamed AE; Galil SMA
    Clin Rheumatol; 2019 Aug; 38(8):2109-2117. PubMed ID: 30915650
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Non-TNF inhibitor switchers versus TNF inhibitor cyclers from multicentre rheumatoid arthritis ultrasonography prospective cohort in Japan.
    Endo Y; Kawashiri SY; Morimoto S; Nishino A; Okamoto M; Tsuji S; Takatani A; Shimizu T; Sumiyoshi R; Igawa T; Koga T; Iwamoto N; Ichinose K; Tamai M; Nakamura H; Origuchi T; Ueki Y; Yoshitama T; Eiraku N; Matsuoka N; Okada A; Fujikawa K; Hamada H; Tsuru T; Nagano S; Arinobu Y; Hidaka T; Tada Y; Kawakami A
    Immunol Med; 2020 Sep; 43(3):115-120. PubMed ID: 32393150
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Costs of Providing Infusion Therapy for Rheumatoid Arthritis in a Hospital-based Infusion Center Setting.
    Schmier J; Ogden K; Nickman N; Halpern MT; Cifaldi M; Ganguli A; Bao Y; Garg V
    Clin Ther; 2017 Aug; 39(8):1600-1617. PubMed ID: 28716293
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Subcutaneous tocilizumab: recent advances for the treatment of rheumatoid arthritis.
    Ogata A; Kato Y; Higa S; Maeda K
    Expert Opin Drug Deliv; 2019 Jun; 16(6):639-648. PubMed ID: 31088167
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of switching from intravenous to subcutaneous formulation of tocilizumab in patients with rheumatoid arthritis.
    Iwamoto N; Fukui S; Umeda M; Nishino A; Nakashima Y; Suzuki T; Horai Y; Nonaka F; Okada A; Koga T; Kawashiri SY; Fujikawa K; Aramaki T; Ichinose K; Hirai Y; Tamai M; Nakamura H; Terada K; Nakashima M; Mizokami A; Origuchi T; Eguchi K; Ueki Y; Kawakami A
    Mod Rheumatol; 2016 Sep; 26(5):662-6. PubMed ID: 26708444
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Guidelines for the management of rheumatoid arthritis].
    Kawahito Y
    Nihon Rinsho; 2016 Jun; 74(6):939-43. PubMed ID: 27311182
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Change from subcutaneous to intravenous abatacept and back in patients with rheumatoid arthritis as simulation of a vacation: a prospective phase IV, open-label trial (A-BREAK).
    Mueller RB; Gengenbacher M; Richter S; Dudler J; Möller B; von Kempis J
    Arthritis Res Ther; 2016 Apr; 18():88. PubMed ID: 27074795
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Subcutaneous abatacept in rheumatoid arthritis: current update.
    Keystone E; Alkhalaf A; Makkawy M
    Expert Opin Biol Ther; 2015; 15(8):1221-30. PubMed ID: 26160492
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Usability and Acceptability of the Abatacept Pre-Filled Autoinjector for the Subcutaneous Treatment of Rheumatoid Arthritis.
    Schiff M; Koo J; Jin E; Schiller E; Day A; Stevens R; Laskar C
    Adv Ther; 2016 Feb; 33(2):199-213. PubMed ID: 26833303
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mass Switch From Intravenous to Subcutaneous Tocilizumab in Rheumatic Diseases During the SARS-COV-2 Pandemic.
    Cáceres VA; Piñeiro ML; Ibáñez-Beróiz B; Enguita-Germán M
    J Clin Rheumatol; 2022 Oct; 28(7):346-348. PubMed ID: 35667380
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety of subcutaneous versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with rheumatoid arthritis.
    McLaughlin M; Östör A
    Expert Opin Drug Saf; 2015 Mar; 14(3):429-37. PubMed ID: 25553607
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic and Pharmacodynamic Analysis of Subcutaneous Tocilizumab in Patients With Rheumatoid Arthritis From 2 Randomized, Controlled Trials: SUMMACTA and BREVACTA.
    Abdallah H; Hsu JC; Lu P; Fettner S; Zhang X; Douglass W; Bao M; Rowell L; Burmester GR; Kivitz A
    J Clin Pharmacol; 2017 Apr; 57(4):459-468. PubMed ID: 27599663
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-citrullinated protein antibody titre as a predictor of abatacept treatment persistence in patients with rheumatoid arthritis: a prospective cohort study in Japan.
    Endo Y; Koga T; Kawashiri SY; Morimoto S; Nishino A; Okamoto M; Eguchi M; Tsuji S; Takatani A; Shimizu T; Sumiyoshi R; Igawa T; Iwamoto N; Ichinose K; Tamai M; Nakamura H; Origuchi T; Ueki Y; Yoshitama T; Eiraku N; Matsuoka N; Okada A; Fujikawa K; Hamada H; Tsuru T; Nagano S; Arinobu Y; Hidaka T; Tada Y; Kawakami A
    Scand J Rheumatol; 2020 Jan; 49(1):13-17. PubMed ID: 31402744
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.